Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Eszopiclone (Lunesta) In San Francisco,.cde2"

Looking for quality documents?
corporate icon
Biologics
Challenge: Complex upstream systems require continuous nutrient profiling and metabolite monitoring to prevent culture collapse or batch failure. Traditional sampling methods are time-consuming and disruptive. Our Solution: REBEL XT and Maven enable real-time profiling of amino acids, glucose, lactate, and ammonia to ensure optimal feed strategies and cellular performance.
external link icon
Repligen Announces Robert A. Spurr Joins Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer
external link icon
Repligen Reports First Quarter 2025 Financial Results
Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth Orders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had a strong start to the year with $169 million of revenue, which represented 14% organic non-COVID growth and helped drive meaningful adjusted operating margin expansion. Total orders grew nearly 20%, with all four franchises growing double-digits, highlighting the momentum in
external link icon
Repligen Reports First Quarter 2024 Financial Results
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “We delivered a solid first quarter, with revenue of $151 million and are on track to achieving our first half sales target of $300 to $310 million. For the quarter, our book-to-bill ratio was 0.99 and over the past nine months we achieved a book-to-bill of 1.03; indicative that our markets are recovering, albeit slowly. On a franchise level, our Filtration franchise
external link icon
Repligen Reports Third Quarter 2018 Financial Results
Record quarterly revenue of $49.5 million represents 35% year-over-year growth Revenue guidance raised to $191-$194 million for full year 2018 WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter and first nine months of 2018. Provided in this press release are financial highlights for the three- and nine-month periods ended September 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “Our third quarter financial performance was highlighted by across the board strength with overall 24% organic revenue growth. Spectrum product sales continued to exceed our expectations, delivering 28% pro forma growth during the third quarter compared to the same period in 2017, and tracking ahead of plan on 2018 revenue
external link icon
Repligen Reports First Quarter 2018 Financial Results
Record quarterly revenue of $44.8M represents 46% year-over-year growth Revenue guidance raised to $182-$188 million for full year 2018 WALTHAM, Mass., May 08, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2018. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2018 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We had a strong start to the year led by sales of our direct filtration and chromatography products, which were up by over 90% year-on-year. This includes our Spectrum business, which continues to outperform our expectations. We are also excited about the depth of our R&D pipeline which is generating new products, including our recently launched OPUS 80R pre-packed columns
external link icon
Repligen Reports Third Quarter 2017 Financial Results
Record quarterly revenue of $36.6 million represents 48% year-over-year growth
Year-to-date revenue of $99.6 million represents 26% year-over-year growth Spectrum contributes revenue of $7.6 million in first two months of ownership WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter ended September 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by updated financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said “I’m very pleased with our overall performance in the third quarter. We closed on the Spectrum acquisition in August and our new colleagues delivered terrific results, with greater than 30% year-on-year revenue growth for the first two months of ownership.
external link icon
Repligen Reports First Quarter 2017 Financial Results
Record quarterly revenue of $30.6 million reflects 22% year-over-year growth or 24% at constant currency
Company increases net income and EPS guidance WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2017. Detailed in this press release are the Company's performance highlights for the quarter, followed by financial guidance for the year 2017 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer, said, “We had a strong start to the year, reporting first quarter revenue growth of 24% at constant currency.  Our Chromatography and Filtration businesses were major drivers of growth in the quarter, with our two acquisitions from 2016 – Atoll GmbH and TangenX Technology Corporation – contributing to the overall success. With a positive outlook
external link icon
Repligen Reports Third Quarter 2016 Financial Results
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the third quarter ended September 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “During the third quarter of 2016, product sales grew to $24.7 million, an increase of 25% from the same period in 2015. Our continued growth during the quarter was driven by strong demand for our direct portfolio of products, in particular our XCell™ ATF systems and OPUS ® columns. It was also an important period with respect to advancing new products, with the launch of a single-use version of our XCell™ ATF system, and the introduction of a new resin recovery feature on our large OPUS ®
external link icon
Repligen Reports First Quarter 2016 Financial Results
WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the first quarter ended March 31, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer, said, “Our record revenue during the first quarter reflects overall growth of 21% year-over-year, driven by increased demand for our proprietary products, which we believe is a direct result of our commercial expansion in 2015. We continue to add best-in-class technologies to our portfolio, and we closed out the quarter by executing on our acquisition strategy with our April 1 st purchase of Atoll GmBH (“Atoll”). We are pleased with how the integration is progressing and look forward to